Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy

[1]  L. Paz-Ares,et al.  Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review. , 2022, JAMA oncology.

[2]  H. Mann,et al.  Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN , 2022, ESMO open.

[3]  B. D’Souza,et al.  Sarcopenia is a strong predictive factor of clinical and oncological outcomes following curative colorectal cancer resection , 2021, ANZ journal of surgery.

[4]  V. Seshan,et al.  Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors , 2021, Nature Communications.

[5]  N. Reinmuth,et al.  Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Robson,et al.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. , 2021, Cancer cell.

[7]  J. Sage.  Faculty Opinions recommendation of SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[8]  C. Rudin,et al.  Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Mohile,et al.  Cachexia and Sarcopenia in Older Adults with Cancer: A Comprehensive Review , 2019, Cancers.

[10]  Young Hak Kim,et al.  Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial , 2019, The Lancet.

[11]  Michelle Fiander,et al.  Tumor mutational burden in lung cancer: a systematic literature review , 2019, Oncotarget.

[12]  J. Kleijnen,et al.  Sarcopenia and ovarian cancer survival: a systematic review and meta‐analysis , 2019, Journal of cachexia, sarcopenia and muscle.

[13]  J. Spicer,et al.  Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer , 2019, Front. Immunol..

[14]  Jinming Yu,et al.  Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer , 2019, Journal of Hematology & Oncology.

[15]  Rong Wang,et al.  Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis , 2019, Cancer management and research.

[16]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[17]  Robert R. Wolfe,et al.  Hypoalbuminemia: Pathogenesis and Clinical Significance , 2018, JPEN. Journal of parenteral and enteral nutrition.

[18]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[19]  René Rizzoli,et al.  Sarcopenia: revised European consensus on definition and diagnosis , 2018, Age and ageing.

[20]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[21]  G. Spolverato,et al.  Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers , 2018, Journal of Gastrointestinal Surgery.

[22]  J. Szustakowski,et al.  Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2018, Cancer cell.

[23]  Lin Guo,et al.  Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L , 2016, Tumor Biology.

[24]  H. Pei,et al.  Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis , 2015, Clinics.

[25]  Qing Yang,et al.  Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis , 2015, Scientific Reports.

[26]  C. Rudin,et al.  Small cell lung cancer: Where do we go from here? , 2015, Cancer.

[27]  I. Tannock,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[28]  D. Gupta,et al.  Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature , 2010, Nutrition journal.

[29]  E. Wouters,et al.  Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. , 1999, Clinical science.

[30]  R. Baumgartner,et al.  Serum albumin is associated with skeletal muscle in elderly men and women. , 1996, The American journal of clinical nutrition.

[31]  A. Ochsenbein,et al.  Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. , 1994, Metabolism: clinical and experimental.

[32]  Qi Huang,et al.  Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis. , 2016, Cancer biomarkers : section A of Disease markers.

[33]  F. Tas,et al.  Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. , 1999, Acta oncologica.

[34]  J. Pujol,et al.  Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. , 1998, Cancer detection and prevention.